ETF Holdings Breakdown of IRWD

News associated with IRWD

Tower Research Capital LLC TRC Boosts Stock Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Tower Research Capital LLC TRC increased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) by 1,130.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,521 shares of the biotechnology company’s stock after buying an additional 16,097 shares during the quarter. […] - 2025-05-11 09:36:52

XTX Topco Ltd Invests $203,000 in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

XTX Topco Ltd bought a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund bought 45,881 shares of the biotechnology company’s stock, valued at approximately $203,000. Other institutional investors have also recently modified their holdings of the company. Journey Strategic Wealth LLC purchased a new stake […] - 2025-04-28 08:11:01

Ironwood Raises 2025 Adj. EBITDA Outlook

(RTTNews) - Ironwood Pharmaceuticals (IRWD) reiterated full year 2025 LINZESS U.S. net sales and total Ironwood revenue guidance and increased adjusted EBITDA guidance. The company has raised full-year 2025 adjusted EBITDA guidance to greater than $105 million as it no longer pla - 2025-04-25 11:22:36

Federated Hermes Inc. Makes New Investment in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Federated Hermes Inc. purchased a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 370,476 shares of the biotechnology company’s stock, valued at approximately $1,641,000. Federated Hermes Inc. owned […] - 2025-04-15 07:54:50

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives $8.60 Consensus Price Target from Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month […] - 2025-04-14 06:01:00

Intech Investment Management LLC Acquires 13,205 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Intech Investment Management LLC boosted its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) by 30.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 57,244 shares of the biotechnology company’s stock after buying an additional 13,205 shares during the quarter. Intech Investment […] - 2025-03-27 08:28:55

15,147 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd acquired a new position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) in the 4th quarter, HoldingsChannel.com reports. The fund acquired 15,147 shares of the biotechnology company’s stock, valued at approximately $67,000. A number of other institutional investors also recently bought and sold shares of IRWD. Pacer Advisors […] - 2025-03-06 10:44:39

IRWD institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	96,274	USD 67,382 -13.2%
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	14,038	USD 9,825 -13.2%
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	71,294	USD 49,899 -13.2%
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	71,294	USD 49,899 -13.2%
Total =		252,900	USD 177,005

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer